Antiviral Drug News and Research

RSS

CDC reports on its Mpox response

Research paper provides an overview of the U.S. monkeypox outbreak, highlighting the rapid response, vaccination efforts, and racial disparities in cases. Ongoing surveillance, vaccination, and communication are emphasized as crucial for future prevention.

24 May 2023

Study reveals CMPK-2 protein-coding gene as a potent inhibitor of flaviviruses

CMPK2 identified as a potential pan-flavivirus inhibitor, restricting virus replication and providing a basis for developing new antiviral treatments.

23 Apr 2023

Newly designed molecule disrupts the infection mechanism of SARS-CoV-2

A team of scientists led by the Department of Energy's Oak Ridge National Laboratory designed a molecule that disrupts the infection mechanism of the SARS-CoV-2 coronavirus and could be used to develop new treatments for COVID-19 and other viral diseases.

28 Mar 2023

New molecule slows the effects of one of SARS-CoV-2's more dangerous components

Researchers have designed a molecule that slows the effects of one of SARS-CoV-2's more dangerous components – an enzyme called a protease that cuts off the immune system's communications and helps the virus replicate.

28 Mar 2023

Nasally administered molecule effective in preventing all SARS-CoV-2 variants

Researchers have developed a molecule that is, when administered nasally, extremely effective in preventing the disease caused by all known variants of the SARS-CoV-2 virus.

24 Mar 2023

Molnupiravir-related mutational signatures among COVID-19 patients

Researchers explore a mutational signature related to molnupiravir in SARS-CoV-2 sequencing datasets.

3 Feb 2023

Antiviral activity of natural flavonoids against various coronaviruses

A recent study describes the binding affinity and docking sites of several natural compounds, as well as their inhibitory activity against 3CLpro.

29 Jan 2023

Researchers identify inhibitors of the SARS-CoV-2 Nsp14 N7-methyltransferase

A recent study identified inhibitors for SARS-CoV-2 non-structural protein 14 (Nsp14).

17 Jan 2023

New research identifies natural compounds with pan-SARS-CoV-2 inhibitory activity

Scientists have recently conducted a cell-based high-content screening of over 300 natural compounds and identified three compounds with potent antiviral activities against SARS-CoV-2 and its variants.

12 Jan 2023

New research on nirmatrelvir resistance in SARS-CoV-2 using powerful replicon cell culture systems

In a recent study posted to the bioRxiv* preprint server, researchers at Emory University used severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Washington (WA.1) and Omicron (BA.1) strains to test for mutations that could result in resistance to the antiviral drug nirmatrelvir.

8 Jan 2023

Traditional Chinese medicine may help treat neurodegenerative diseases caused by HSV-1 reactivation

Announcing a new publication for Acta Materia Medica journal. Owing to environmental and lifestyle changes in modern society, physical and mental stress is on the rise among the population in attempting to compensate for the changes.

3 Jan 2023

What is the incidence of viral rebound after treatment with nirmatrelvir-ritonavir and molnupiravir?

Researchers evaluated the incidence of COVID-19 rebound among SARS-CoV-2 -positive patients treated with oral antiviral drugs such as nirmatrelvir-ritonavir combination and molnupiravir.

12 Dec 2022

Researchers seek to reduce Chikungunya virus-caused joint pain with new drug

Oregon Health & Science University researchers and partners are developing what could become the first-ever treatment against the debilitating joint pain that can last months or years after becoming infected with the emerging Chikungunya virus.

9 Dec 2022

Miracles Start in the Lab: the quest to find a vaccine to cure AIDS

To commemorate World AIDS Day, News Medical spoke to Dr. Larry Corey, an internationally renowned expert in virology, immunology, and vaccine development, and the former president and director of Fred Hutch, about his work within the field of HIV/AIDS research and vaccine development.

30 Nov 2022

Pregnant people can safely take Paxlovid to reduce the possibility of severe COVID-19, study shows

Findings from a Johns Hopkins Medicine research study published today in JAMA Network Open provide strong evidence that people who are pregnant and have been infected with SARS-CoV-2 (the virus that causes COVID-19) can safely take the antiviral drug Paxlovid to reduce the possibility of severe disease.

29 Nov 2022

The potential of Sofosbuvir against COVID-19 neurological symptoms

Researchers discuss how SARS-CoV-2 infects cortical neurons and damages their synapses that form the connection between brain cells.

25 Nov 2022

Study aims to develop broad-spectrum antivirals against SARS-CoV-2 via drug repurposing strategies

This study aims to determine which FDA-approved compound(s) can be repurposed as a broad-spectrum antiviral drug(s) against SARS-CoV-2 and variants.

24 Nov 2022

NIAID awards more than $12 million for the development of antiviral therapies

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, recently awarded more than $12 million to three institutions for the development of antiviral therapies to treat diseases caused by viruses with pandemic potential.

21 Nov 2022

Evaluating differences in viral and symptom rebounds between Paxlovid-treated and untreated COVID-19 patients

Researchers evaluated differences in viral and symptom rebounds between Paxlovid-treated and untreated coronavirus disease 2019 (COVID-19) patients.

17 Nov 2022

Study concludes monkeypox virus is readily detected by qPCR using three clinically validated assays

Researchers validated monkeypox virus (MPXV) quantitative polymerase chain reaction (qPCR) assays.